Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Bahriye Aktas"'
Autor:
Davut Dayan, Kristina Ernst, Bahriye Aktas, Raffaela Baierl, Susanne Briest, Martin Dengler, Daniela Dieterle, Amelie Endres, Kathrin Engelken, Andree Faridi, Hannes Frenz, Peer Hantschmann, Wolfgang Janni, Christina Kaiser, Thorsten Kokott, Stefanie Laufhütte, Florian Schober, Florian Ebner
Publikováno v:
Current Oncology, Vol 29, Iss 11, Pp 8874-8885 (2022)
Purpose: Surgical interventions tend to have an effect on the generation of recurrences in tumor patients due to the anesthesia involved as well as tissue damage and subsequent inflammation. This can also be found in patients with breast cancer. Meth
Externí odkaz:
https://doaj.org/article/2f6baa75214947b087c2d2f2b11beabf
Autor:
Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, Matthias Christgen, Ronald Kates, Eva Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Sherko Kuemmel, Rachel Wuerstlein, Monika Graeser, Ulrike Nitz, Hans Kreipe, Oleg Gluz, Nadia Harbeck
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-13 (2022)
Abstract Background Higher density of stromal tumor-infiltrating lymphocytes (sTILs) at baseline has been associated with increased rates of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (
Externí odkaz:
https://doaj.org/article/8e767ca38fb44eb2b85c5566cfa49c03
Autor:
Isabel Grote, Stephan Bartels, Leonie Kandt, Laura Bollmann, Henriette Christgen, Malte Gronewold, Mieke Raap, Ulrich Lehmann, Oleg Gluz, Ulrike Nitz, Sherko Kuemmel, Christine zuEulenburg, Michael Braun, Bahriye Aktas, Eva‐Maria Grischke, Claudia Schumacher, Kerstin Luedtke‐Heckenkamp, Ronald Kates, Rachel Wuerstlein, Monika Graeser, Nadia Harbeck, Matthias Christgen, Hans Kreipe
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8581-8594 (2021)
Abstract Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying pri
Externí odkaz:
https://doaj.org/article/2c544d649b024c5bbd721b91d7f7c740
Autor:
Monika Graeser, Nadia Harbeck, Oleg Gluz, Rachel Würstlein, Christine zu Eulenburg, Claudia Schumacher, Eva-Maria Grischke, Helmut Forstbauer, Moritz Dimpfl, Michael Braun, Matthias Christgen, Hans Heinrich Kreipe, Jochem Potenberg, Raquel von Schumann, Bahriye Aktas, Cornelia Kolberg-Liedtke, Sherko Kümmel, Ulrike Nitz
Publikováno v:
Breast, Vol 59, Iss , Pp 58-66 (2021)
Objective: We assessed the value of breast ultrasound (US) performed at week 3 and 6 and at the end (EOT) of neoadjuvant therapy (NAT) for prediction of pathologic complete response (pCR, ypT0/is ypN0) in patients with HR+/HER2+, HR-/HER2-or HR-/HER2
Externí odkaz:
https://doaj.org/article/5a1f7a16eaed4e7f94e246831a6ca2c9
Autor:
Monika Graeser, Simone Schrading, Oleg Gluz, Kevin Strobel, Christopher Herzog, Lale Umutlu, Alex Frydrychowicz, Dorothea Rjosk-Dendorfer, Rachel Würstlein, Ralph Culemann, Christine Eulenburg, Jascha Adams, Henrik Nitzsche, Anna Prange, Sherko Kümmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Jochem Potenberg, Raquel von Schumann, Bahriye Aktas, Cornelia Kolberg-Liedtke, Nadia Harbeck, Christiane K. Kuhl, Ulrike Nitz
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-13 (2021)
Abstract Background Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes. Methods Imaging was performed after 12-week NAT in patients
Externí odkaz:
https://doaj.org/article/2b0e3db5c69b4345bac7835ff7078f9c
Publikováno v:
Cancers, Vol 15, Iss 3, p 568 (2023)
Background: Patients with hormone-receptor-positive (HR+) breast cancer are at increased risk for late recurrence. One reason might be disseminated tumor cells (DTCs), which split off in the early stages of the disease and metastasize into the bone m
Externí odkaz:
https://doaj.org/article/2ff3301f6b0542e29adca40f9bba894f
Publikováno v:
Cancers, Vol 14, Iss 17, p 4101 (2022)
In breast cancer, the genetic profiling of circulating cell-free DNA (cfDNA) from blood plasma was shown to have good potential for clinical use. In contrast, only a few studies were performed investigating urinary cfDNA. In this pilot study, we anal
Externí odkaz:
https://doaj.org/article/164a2511f71943b5ba1fbe0d2fb1cd26
Autor:
Eva-Maria Grischke, Nadia Harbeck, Michael Braun, Katarzyna Jozwiak, Michael Hauptmann, Claudia Schumacher, Monika Graeser, Friedrich Feuerhake, Oleg Gluz, Valery Volk, Matthias Christgen, Sherko Kuemmel, Helmut Forstbauer, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Cornelia Kolberg-Liedtke, Ronald Kates, Rachel Wuerstlein, Ulrike Nitz, Hans Heinrich Kreipe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background The association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in triple-negative breast cancer (TNBC) remains unexplored.Methods Multiplexed immunohistochemistry
Externí odkaz:
https://doaj.org/article/2aeee82f7d4040a2a3560c86347de744
Publikováno v:
Cancers, Vol 14, Iss 8, p 1863 (2022)
In breast cancer therapeutic decisions are based on the expression of estrogen (ER), progesterone (PR), the human epidermal growth factor 2 (HER2) receptors and the proliferation marker Ki67. However, only little is known concerning heterogeneity bet
Externí odkaz:
https://doaj.org/article/7a21f491dc7e4af6ae56249fdf6cf175
Autor:
Ulrike Nitz, Oleg Gluz, Hans H. Kreipe, Matthias Christgen, Sherko Kuemmel, Frederick L. Baehner, Steven Shak, Bahriye Aktas, Michael Braun, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Benno Nuding, Maren Darsow, Claudia Schumacher, Katja Krauss, Wolfram Malter, Marc Thill, Mathias Warm, Rachel Wuerstlein, Ronald E. Kates, Nadia Harbeck
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human epidermal grow
Externí odkaz:
https://doaj.org/article/115b004b52414ec081eca0fe5b0d1c40